Branch² Intelligence
AstraZeneca in £20bn hit after heart disease drug hoped to be a potential blockbuster flops in trials
Key takeaway
AstraZeneca's Wainua drug fails heart disease trial, wiping £20bn from market cap.
- Step 1AstraZeneca's Wainua fails Phase III heart disease trial, triggering 10.5% share drop and £20bn market cap loss.
- Step 2Ionis Pharmaceuticals, co-developer, loses expected milestone and royalty revenue, impacting its valuation.
- Step 3Competitors with approved or advanced cardiovascular drugs (e.g., Novartis, Amgen) gain market share and pipeline confidence.
Source: This Is Money
This is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.